02:50 AM EDT, 09/11/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We keep our target price of USD61, implying 16.3x our 2025 EPADS, a discount to historical forward P/E of 25x-30x to reflect growing concerns about long-term competitive positioning, yet above peer average of 13x given NOVO's superior margins. NOVO announced a sweeping transformation plan on September 10 that includes cutting 9,000 jobs to deliver DKK8 billion in annualized savings by the end of 2026, though the initiative carries DKK8 billion in net restructuring charges and prompted the third operating profit guidance cut this year (now 4%-10% growth at constant exchange rates vs. the prior 10%-16%). We reduce EPS forecasts to DKK23.90 (from DKK25.10) for 2025 and DKK27.15 (from DKK28.10) for 2026. We think the plan underscores management's urgency to revive momentum amid pressures on the obesity franchise, with the transformation potentially strengthening long-term positioning through reinvestment in growth opportunities, though near-term profitability expectations no longer clearly outpace European peers.